Study design for mouse asthma model.
- Masanori Sawada (206470)
- Tomotaka Kawayama (24281)
- Haruki Imaoka (206479)
- Yuki Sakazaki (206464)
- Hanako Oda (206474)
- Shin-ichi Takenaka (206477)
- Yoichiro Kaku (286432)
- Koichi Azuma (150783)
- Morihiro Tajiri (286433)
- Nobutaka Edakuni (286435)
- Masaki Okamoto (286437)
- Seiya Kato (206493)
- Tomoaki Hoshino (24282)
Publication date
February 2013
DOIAbstract
<p>Group 1: ovalbumin (OVA)-sensitized mice injected intraperitoneally with 10 µg of OVA plus 4 mg of Al (OH)3 on day 0 and 5 and saline-challenged on day 18 with 0.9% saline for 20 min; group 2: OVA-sensitized mice injected intraperitoneally with OVA on day 0 and 5 and OVA-challenged on day 18 with 5% OVA (w/v) in 0.9% saline for 20 min; group 3: ovalbumin (OVA)-sensitized mice injected intraperitoneally on day 0 and 5, treated with an intra-peritoneal injection of purified 500 µg of rat anti-mouse CD4 monoclonal antibody (mAb) (GK1.5, rat IgG2b, k) or rat IgG (Sigma–Aldrich Chemical) on day 17 and OVA-challenged on day 18, the airway hyperresponsiveness (AHR) and bronchoalveolar lavage fluid (BALF) were analyzed in all mice.</p
Add to ORKG